Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC
Last updated: July 2026

DoxyPEP and Antibiotic Resistance: What the Surveillance Actually Shows

Resistance is the one legitimate scientific objection to DoxyPEP, and it deserves a straight answer instead of either dismissal or panic. The short version has shifted over the past year: chlamydia and syphilis protection still looks solid, but gonorrhea protection is eroding in places where resistant strains have spread — and the newest surveillance shows why. This page tracks the current evidence and gets updated as new data lands.

What "resistance" actually means here

Doxycycline works by blocking a bacterium's ability to make proteins. Some bacteria carry genes that let them pump the drug out or shield the target it binds to — tetM is the gene public-health labs track most closely for gonorrhea, because it confers high-level resistance that a standard 200 mg dose can't overcome. A strain carrying tetM isn't "immune" to doxycycline in some absolute sense — it's just no longer reliably stopped by it. That's different from resistance to ceftriaxone, the injectable antibiotic that's the actual frontline treatment if you test positive for gonorrhea; DoxyPEP doesn't use ceftriaxone, so a DoxyPEP failure and a ceftriaxone failure are separate questions, addressed below.

What the newest surveillance actually shows

Three data points, from most to least reassuring:

Chlamydia and syphilis protection is holding up. A CDC-funded analysis of Kaiser Permanente Southern California patients (2023–2025) found DoxyPEP's real-world effectiveness was about 67% against chlamydia and 61% against syphilis across the full study period — consistent with the original trial data and not showing signs of erosion.

Gonorrhea protection has declined sharply as local resistance has spread. The same study found DoxyPEP's effectiveness against gonorrhea fell from about 42% before statewide rollout to roughly –15% (meaning no measurable protection) by early 2025, tracking closely with the local share of gonorrhea isolates carrying tetM: effectiveness was around 47% when tetM was present in 20–30% of local isolates, and had dropped to essentially zero once tetM reached half of isolates. Separately, CDC surveillance data show the national share of tetM-carrying gonorrhea isolates rose from under 10% in 2020 to over 30% by early 2024, with the increase accelerating after DoxyPEP trial results were first publicized in 2022. This is a single regional study and hasn't yet completed peer review as of this writing, but it's the most direct look yet at whether DoxyPEP's protection changes as resistance spreads locally — and the answer, for gonorrhea, appears to be yes.

Ceftriaxone still works, but there's an early signal worth watching. A substudy of the French DOXYVAC trial found that men using DoxyPEP developed high-level tetM resistance significantly more often than those not using it (about 36% vs. 13% of gonorrhea isolates). Every isolate in that study remained fully treatable with ceftriaxone and cefixime — no treatment failures occurred — but isolates carrying a specific genetic marker linked to reduced cefixime susceptibility were more common in the DoxyPEP group (about 32% vs. 10%). That's a molecular early-warning signal, not evidence that DoxyPEP is currently causing treatment-resistant gonorrhea; researchers flagged it specifically so it gets watched closely as use expands.

Does this mean DoxyPEP doesn't work anymore?

No — it means the answer depends on which infection and, increasingly, on local resistance patterns. For chlamydia and syphilis, the case for DoxyPEP looks about as strong as it did at launch. For gonorrhea, DoxyPEP is behaving less like reliable prevention and more like a coin flip in places where resistant strains have taken hold — which is a meaningfully different, weaker claim than the original trial data suggested, and part of why CDC still frames gonorrhea protection as "in some studies" rather than a settled number. Regular testing every 3–6 months matters more than ever, specifically because DoxyPEP can no longer be assumed to be catching gonorrhea exposures the way it reliably catches chlamydia and syphilis.

What about resistance beyond gonorrhea?

Gonorrhea gets the most attention because it's the STI DoxyPEP was weakest against to begin with, but it's not the only organism researchers are watching. Studies of DoxyPEP-eligible populations have found that Staphylococcus aureus (a common skin bacterium, including MRSA) carried on the body is more often tetracycline-resistant in people using DoxyPEP, and that resistant strains are also more likely to be resistant to other unrelated antibiotics (trimethoprim-sulfamethoxazole and clindamycin) — a pattern researchers call co-resistance. This matters less for your own DoxyPEP effectiveness and more for what happens if you or someone else later needs one of those other antibiotics for an unrelated skin or soft-tissue infection. CDC's own guidance is candid that the effect of DoxyPEP on the broader microbiome — the bacteria that live on skin and in the gut — is still an open research question, not a settled one.

Why CDC's recommendation hasn't changed (yet)

It's a fair question: if gonorrhea protection is eroding, why does CDC guidance still recommend DoxyPEP? Two reasons CDC has given: first, the guidance already targets a narrower group — gay/bi men and transgender women with a bacterial STI in the past year — specifically to concentrate the benefit where trial evidence is strongest and limit population-wide antibiotic pressure. Second, even with gonorrhea protection weakening, the combined reduction in chlamydia and syphilis is still judged to outweigh the resistance risk for that group, provided people keep testing regularly so breakthrough infections get caught and treated. CDC has said explicitly that it's using existing surveillance systems to track resistance trends and prescribing rates as the guidance is implemented, and that the recommendation could change as more data comes in. This page will be updated when it does.

What this means for you

If you're already using DoxyPEP: keep using it as prescribed, and don't skip your 3–6 month follow-up testing — that's now the main way you'd catch a gonorrhea exposure DoxyPEP didn't prevent. If you're deciding whether to start, this evidence doesn't erase the case for DoxyPEP (chlamydia and syphilis protection is real and current), but it's a legitimate topic to raise with your prescriber, especially if gonorrhea is your primary concern or you're in an area with known high resistance rates. Either way, this is exactly the kind of individualized, evolving-evidence decision a clinician conversation is for, not a one-size-fits-all answer.

Go deeper